Validating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulation
<p><b>Introduction:</b> Cognitive decline is one the most common and debilitating non-motor symptoms associated with Parkinson’s disease. Currently, no treatment options exist for cognitive impairment in PD, partly due to the lack of measurement tools sensitive to the subtle early...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
2019
|
| Subjects: |
| _version_ | 1817932273854447616 |
|---|---|
| author | Nahon, S |
| author2 | Harmer, C |
| author_facet | Harmer, C Nahon, S |
| author_sort | Nahon, S |
| collection | OXFORD |
| description | <p><b>Introduction:</b> Cognitive decline is one the most common and debilitating non-motor symptoms associated with Parkinson’s disease. Currently, no treatment options exist for cognitive impairment in PD, partly due to the lack of measurement tools sensitive to the subtle early cognitive changes and pro-cognitive pharmacological manipulation in the disease. Implicit cognition shows promise in detecting these otherwise overlooked changes.</p>
<p><b>Methods:</b> Two studies were performed. One between-subject study comparing the performance of healthy controls (n=30), REM sleep behaviour disorder (n=30), a prodromal population for Parkinson’s disease, and Parkinson’s disease (n=30) on a previously validated battery of implicit cognitive tasks. The second was a blinded and randomized within-subject study looking at performance on the same implicit task battery in patients with Parkinson’s disease (n=30) on two occasions, both ‘on’ and ‘off’ their dopaminergic medication.</p>
<p><b>Results:</b> The first study successfully detected implicit cognitive difference in RBD individuals compared to healthy controls and Parkinson’s disease, specifically on the positive location priming effect. The second study failed to detect any changes between Parkinson’s patients ‘on’ and ‘off’ their medication, although there was an effect on an explicit measure of visuospatial memory.</p>
<p><b>Conclusion:</b> These results indicate that visuospatial positive priming could be a promising avenue of future research in detecting the early cognitive changes associated with PD. These results also indicate that implicit cognition may not be sensitive to pharmacological manipulation in PD.</p> |
| first_indexed | 2024-03-06T19:54:03Z |
| format | Thesis |
| id | oxford-uuid:24f02399-16c9-4efb-9135-9503a4cfb04f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:35:18Z |
| publishDate | 2019 |
| record_format | dspace |
| spelling | oxford-uuid:24f02399-16c9-4efb-9135-9503a4cfb04f2024-12-01T18:52:17ZValidating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulationThesishttp://purl.org/coar/resource_type/c_bdccuuid:24f02399-16c9-4efb-9135-9503a4cfb04fPsychiatryPsychopharmacologyEnglishHyrax Deposit2019Nahon, SHarmer, CMurphy, S<p><b>Introduction:</b> Cognitive decline is one the most common and debilitating non-motor symptoms associated with Parkinson’s disease. Currently, no treatment options exist for cognitive impairment in PD, partly due to the lack of measurement tools sensitive to the subtle early cognitive changes and pro-cognitive pharmacological manipulation in the disease. Implicit cognition shows promise in detecting these otherwise overlooked changes.</p> <p><b>Methods:</b> Two studies were performed. One between-subject study comparing the performance of healthy controls (n=30), REM sleep behaviour disorder (n=30), a prodromal population for Parkinson’s disease, and Parkinson’s disease (n=30) on a previously validated battery of implicit cognitive tasks. The second was a blinded and randomized within-subject study looking at performance on the same implicit task battery in patients with Parkinson’s disease (n=30) on two occasions, both ‘on’ and ‘off’ their dopaminergic medication.</p> <p><b>Results:</b> The first study successfully detected implicit cognitive difference in RBD individuals compared to healthy controls and Parkinson’s disease, specifically on the positive location priming effect. The second study failed to detect any changes between Parkinson’s patients ‘on’ and ‘off’ their medication, although there was an effect on an explicit measure of visuospatial memory.</p> <p><b>Conclusion:</b> These results indicate that visuospatial positive priming could be a promising avenue of future research in detecting the early cognitive changes associated with PD. These results also indicate that implicit cognition may not be sensitive to pharmacological manipulation in PD.</p> |
| spellingShingle | Psychiatry Psychopharmacology Nahon, S Validating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulation |
| title | Validating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulation |
| title_full | Validating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulation |
| title_fullStr | Validating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulation |
| title_full_unstemmed | Validating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulation |
| title_short | Validating an implicit cognition battery in Parkinson’s disease and assessing its sensitivity to pharmacological manipulation |
| title_sort | validating an implicit cognition battery in parkinson s disease and assessing its sensitivity to pharmacological manipulation |
| topic | Psychiatry Psychopharmacology |
| work_keys_str_mv | AT nahons validatinganimplicitcognitionbatteryinparkinsonsdiseaseandassessingitssensitivitytopharmacologicalmanipulation |